Privosegtor Progress

Oculis Holdings AG (Nasdaq: OCS) reported positive progress in its neuro‑ophthalmology pipeline, with key highlights including the PIONEER program for Privosegtor as a lead late‑stage asset. The FDA has provided pre‑IND feedback supporting the proposed clinical development strategy and regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses. This approval is expected to pave the way for an IND submission by the end of 2026.